Prothena's average Accounts Receivable for the
three
months ended in Mar. 2025 was $0.0 Mil. Prothena's Revenue for the
three
months ended in Mar. 2025 was $2.8 Mil.
Hence, Prothena's Days Sales Outstanding for the
three
months ended in Mar. 2025 was 0.00.
The historical rank and industry rank for Prothena's Days Sales Outstanding or its related term are showing as below:
PRTA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.03 Med: 20.61 Max: 254.16
Current: 13.65
During the past 13 years, Prothena's highest Days Sales Outstanding was 254.16. The lowest was 0.03. And the median was 20.61.
PRTA's Days Sales Outstanding is ranked better than 93.97% of 846
companies
in the Biotechnology industry
Industry Median: 72.28
vs PRTA: 13.65
Prothena's Days Sales Outstanding
declined
from Mar. 2024 (9,415.18) to Mar. 2025 (0.00).
Prothena Days Sales Outstanding Historical Data
The historical data trend for Prothena's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prothena's Days Sales Outstanding
For the Biotechnology subindustry, Prothena's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prothena's Days Sales Outstanding Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prothena's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Prothena's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prothena (NAS:PRTA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Prothena Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Prothena's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRTA has been successfully added to your 